Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

The global influenza medications market size is expected to reach USD 1,386.21 million by 2032, according to a new study by Polaris Market Research. The report “Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The proliferation of seasonal flu, greater prevalence of contagious respiratory illness, and increasing patient population who are at higher risk of developing flu-related complications, are key factors driving the market growth. Growing number of government initiatives like vaccination programs for controlling the spread of influenza and awareness regarding the importance of early diagnosis and treatment of influenza, are further anticipated to propel market growth.

• For instance, according a report by the Centre for Health Protection in September 2023, the Government Vaccination Programme was launched in October 2023 under which the government continued to provide seasonal influenza vaccination for free of cost.

Furthermore, growing research & development activities in the field of influenza medications and growing number of pharmaceutical companies implementing on the development of more effective antiviral drugs that can treat influenza more efficiently through targeting different stages of viral, are further boosting the market’s growth. For instance, according to a report by the University of Oxford in October 2023, the RECOVERY trail has been expanded for investigating treatments for influenza that cause deaths of approx. 290,000 to 650,000 people each year.

As the need for effective and safer antiviral drugs to combat the spread of influenza, companies are introducing innovative antiviral drugs like next-generation antiviral drugs which offer enhanced efficacy, broader spectrum of activity against the several influenza strains, and reduced side effects, which is impacting the demand for influenza medications in a positive way.

Additionally, ongoing advances in personalized medicine tailoring to influenza treatment based on individual patient characteristics like immune response and genetic make-up, further escalating the product demand globally. For instance, according to a study done by the Indian Institute of Science in July 2023, it is reported that picolinic acid has the potential to block various disease-causing viruses including influenza and it also help to fight against several viral diseases.

Influenza Medications Market Report Highlights

• Influenza A segment accounted for notable share, owing to rising incidences and awareness regarding the importance of proper medications
• Oseltamivir phosphate segment held the majority share, that is attributed to its advantages including higher efficiency and effectiveness against several strains
• Online pharmacies segment will grow at highest pace, emergence of online pharmacy platforms offering several benefits to patients like convenience and easy accessibility
• North America dominated the market, on account of prevalence of influenza and rising investments in R&D activities to develop new formulations
• The key market players include Bayer, Roche Diagnostics, Novartis, Sanofi, AstraZeneca, AbbVie, BioCryst Pharmaceuticals, and Mylan

Polaris Market Research has segmented the influenza medications market report based on influenza type, treatment, distribution channel, and region:

Influenza Medications, Influenza Type Outlook (Revenue - USD Million, 2023 - 2032)

• Influenza A
• Influenza B

Influenza Medications, Treatment Outlook (Revenue - USD Million, 2023 - 2032)

• Baloxavir Marboxil
• Oseltamivir Phosphate
• Others

Influenza Medications, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Influenza Medications, Regional Outlook (Revenue - USD Million, 2023 - 2032)

• North America

- U.S.

- Canada

• Europe

- Germany

- UK

- France

- Italy

- Spain

- Russia

- Netherlands

- Rest of Europe

• Asia Pacific

- China

- India

- Japan

- South Korea

- Indonesia

- Malaysia

- Rest of Asia Pacific

• Latin America

- Argentina

- Brazil

- Mexico

- Rest of Latin America

• Middle East & Africa

- UAE

- Saudi Arabia

- Israel

- South Africa

- Rest of Middle East & Africa